SEI Investments’s AbCellera Biologics ABCL Stock Holding History

SEI Investments’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-31,640	Closed	-$321K	–	2678
2022 Q4	$321K	Buy	+31,640	New	+$366K	﹤0.01%	2172

Other funds holding ABCL

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

HMC

Harvard Management Company Boston, Massachusetts $4.26B AUM 5.81% 1-Year Est. Return

FFVM

Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

SEI Investments's ABCL Position: Q1 2023 in Review

SEI Investments sold out of AbCellera Biologics (ABCL) in Q1 2023, closing a stake of 31,640 shares — an estimated $321K sold.

SEI Investments first reported a position in ABCL in Q4 2022 and held it in 1 quarter. The position peaked at $321K in Q4 2022. 183 funds tracked by Wall St. Rank hold ABCL as of Q1 2023.

SEI Investments reported no remaining AbCellera Biologics position as of Q1 2023 after selling out during the quarter.
SEI Investments sold 31,640 AbCellera Biologics shares in Q1 2023, an estimated $321K.
SEI Investments first reported a position in AbCellera Biologics in Q4 2022 and held it in 1 quarter.
SEI Investments's AbCellera Biologics position peaked at $321K in Q4 2022.
183 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2023.

Based on SEI Investments's 13F filing for Q1 2023, filed 12 May 2023.